You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
SBC: BIOFLUIDICA, INC. Topic: 102AbstractAcute myeloid leukemiaAMLis the most common adult leukemia withnew cases expected inin the US and ayear survival rate of onlyThe primary cause of death for AML is due to disease relapseThe consequences of relapse are significant with it not atypical to see a relapse rate ofof which onlysurvive afteryearsIf clinicians could easily identify a patient s minimum residual diseaseMRDbefore the t ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a mobile and automated platform for multiplexed multi-modality imaging
SBC: Sonovol, Inc. Topic: 102Abstract Bioluminescence imagingBLIsystems are installed in thousands of facilities and labsand with their straightforward and low cost workflow for longitudinal studiesare the most commonly used preclinical modality for assessing tumor models in rodentsThere currently is no high throughput and low cost system enabling BLI images to be combined with anatomical images of soft tissue to confirm tumo ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
SBC: Immunext, Inc. Topic: RImmuNext has identified and developed a putative lead anti VISTA monoclonal antibody mAb that we aim to bring to the clinic for the treatment of human autoimmune disease VISTA is a member of the highly successful negative checkpoint regulator NCR family of drug targets whose members have demonstrated proven efficacy in inducing long term remissions in human cancers We contend that antibodie ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery
SBC: BIOKIER, INC. Topic: 200DESCRIPTIONprovided by applicantGlucose homeostasis and regulation of food intake are both promoted by the secretion of gut hormones following nutrient stimulation of enteroendocrine cellsL cellsin the lower gutThis process is impaired in diabetes but is restored when delivery of dietary compounds such as amino acids and fatty acids to the lower gut is facilitatedThis effect of delivery of nutrien ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic Nitric Oxide Sensor
SBC: CLINICAL SENSORS, INC. Topic: NIAIDPROJECT SUMMARY Clinical Sensors has developed a manufacturable prototype microfluidic sensor for measuring nitric oxide in whole bloodThis STTR Phase II project aims to complete several key aims necessary to commercialize this deviceincluding a clinical study where NO levels will be evaluated clinically in sepsisSepsis is the leading cause of death in non cardiac intensive care unitsICUsEach year ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Bioimpedance based Intracranial Mapping for Monitoring Evolving TBI
SBC: RYTEK MEDICAL INC Topic: 105ABSTRACT Approximately million individuals suffer from traumatic brain injury TBI annually with over expected to die as a result of their injury In these most severe cases patients are typically admitted to the intensive care unit ICU for continuous monitoring and treatment of their injury Standard monitoring includes implantation of an intracranial pressure ICP sensor arterial ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Design and Development of Immunotolerant S. aureus Biotherapies
SBC: Lyticon LLC Topic: RThe increasing incidence of multi drug resistance in Staphylococcus aureus and other bacteria represents a public health crisisTwo thirds of hospital associated Saureus infections andof those acquired in the community are now methicillin resistantMRSAMRSA causes rtinfections in the US each yearand it is responsible for half of all US deaths caused by drug resistant bacteriaThis threat to public he ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases
SBC: Eyedesis Biosciences, LLC Topic: NPROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF
SBC: CELDARA MEDICAL, LLC Topic: NHLBIDESCRIPTIONprovided by applicantIdiopathic pulmonary fibrosisIPFkills aboutpersons in the United States each yearThere are currently aroundAmericans afflicted with this fatal disease that typically results in death withinyearsThis year alone another approximatelyAmericans will receive this devastating diagnosisWhile two recently approved drugs reduce the time to decline in certain lung parametersa ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Automated Isolation of Single Cells Using High-Resolution and Subcellular Imaging
SBC: CELL MICROSYSTEMS INC Topic: 400PROJECT SUMMARYPairingdetailedphenotypiccharacterizationofcellswithdownstreammolecularanalysisrepresentsasignificant challengeespecially at the level of single cellsCell Microsystems has developed and commercializedthe CellRaftSystemwhich is currently the only commercially available means of imaging cells using brightfieldand or multichannel fluorescence prior to single cell isolation and downstre ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health